Torbay Hospital first to recruit UK patient for advanced prostate cancer trial

Published: 18 November 2026
Four patients at Torbay and South Devon NHS Foundation Trust are taking part in a pioneering international research trial looking at new ways to treat advanced prostate cancer.
The MK2400-001 study is evaluating whether a targeted drug, called ifinatamab deruxtecan (MK-2400), could offer an alternative to standard chemotherapy for patients whose cancer has spread and continues to grow despite hormone treatment.
Researchers will assess whether the treatment can help patients live longer and slow the progression of the disease, while potentially reducing some of the side effects associated with chemotherapy.
Dominic Gover is one of the patients on the trial. Dominic said: “I was first diagnosed in 2018 and it was Dr Lydon who told me about the trial earlier this year. When I was asked if I’d like to be involved, I didn’t let Dr Lydon finish the sentence – I said yes immediately!
“I started treatment in July and was both excited and anxious, but the team has been so supportive. When I think about my previous treatment and how unwell it made me feel because it attacks everything, I’m hoping this new targeted treatment will have fewer side effects. If everything goes well, I can continue having the treatment indefinitely, which is much longer than the usual standard of care drug.
“It feels like a positive experience has come out of a negative situation and I’m just grateful for the opportunity.”
Unlike traditional chemotherapy, which affects both cancerous and healthy cells, the treatment is designed to target a protein found on prostate cancer cells. It delivers anti-cancer medicine directly into the tumour cells, helping to minimise damage to healthy tissue.
Researchers hope this more targeted approach could improve outcomes and quality of life for patients with advanced prostate cancer.
Dr Anna Lydon, Clinical Oncologist at Torbay and South Devon NHS Foundation Trust and the trial’s Principal Investigator said: “We are always trying to offer patients treatments that don’t upset their daily living unduly and this trial drug offers the real hope of that. We are so pleased to have this trial available to our patients in Torbay and South Devon and are very grateful to those men who are taking part.”
Torbay Hospital is the first site to open the MK2400-001 trial in the UK and the first to recruit a UK patient. The trial closes to recruitment in August 2027.
